Eli Lilly's Manufacturing Moat: Vertical Integration and Fill-Finish Capex Acceleration
How did Novo Holdings' acquisition of Catalent impact Eli Lilly's capital allocation and manufacturing strategy for injectable cardiometabolic therapies?
By Austin Kline
Founder & Lead Analyst · Research methodology
Published 2026-11-13 · Last updated 2026-11-13
Executive summary
Novo Holdings' buyout of Catalent prompted Eli Lilly to accelerate the verticalization of its sterile fill-finish and peptide manufacturing footprint, reducing reliance on merchant CDMOs. Lilly's capital expenditures increased from $3.45 billion in fiscal 2023 to $7.84 billion in fiscal 2025, reaching $5.26 billion in the first six months of 2026. This internal capacity expansion insulates supply chains, lowers unit production costs relative to vendor pricing, and establishes a durable barrier to entry in commercial GLP-1 scale.
Eli Lilly by the numbers
Historical · FY2021–FY2025
Source: Reported annual filings (10-K / 20-F) and provider data. Fiscal years as reported; margins are calculated from the reported figures shown.
Supply Chain Verticalization and Capex Expansion
Added 2026-11-13
Yes. Novo Holdings’ acquisition of Catalent served as a direct catalyst that crystallized and accelerated Eli Lilly’s strategy to aggressively verticalize its sterile fill-finish and peptide manufacturing footprint.
When Novo Holdings moved to acquire Catalent—subsequently transferring three critical fill-finish sites directly to Novo Nordisk—it laid bare the structural vulnerability of relying on merchant Contract Development and Manufacturing Organizations (CDMOs) for injectable cardiometabolic therapies. In response, Lilly chose not to scramble for defensive supply pacts or board-level entanglements with the remaining independent CDMOs; instead, it dramatically increased capital expenditures to bring end-to-end peptide synthesis, sterile vial and syringe filling, and autoinjector assembly entirely within its own corporate perimeter.
1. The Capital Expenditure Trajectory: What the Filings Confirm
The financial evidence of this capex acceleration is clearly documented in Eli Lilly’s regulatory filings.
According to Eli Lilly’s Form 10-K for the fiscal year ended December 31, 2025 (Consolidated Statements of Cash Flows), purchases of property and equipment expanded aggressively as the GLP-1 manufacturing race intensified:
- Fiscal 2023 Capex: $3.45 billion
- Fiscal 2024 Capex: $5.06 billion (a 46.7% increase year-over-year)
- Fiscal 2025 Capex: $7.84 billion (a 55.0% increase year-over-year, and more than double 2023 levels)
That momentum has accelerated further. In Lilly’s Form 10-Q for the quarterly period ended June 30, 2026, capital expenditures for the first six months alone reached $5.26 billion, compared to $3.21 billion in the six months ended June 30, 2025.
In the Executive Overview of its 2025 Form 10-K, management explicitly underscored the strategic intent behind this cash deployment:
"To support anticipated demand for our current and prospective products, we have undertaken significant manufacturing expansion initiatives. Additional capacity is expected to become operational over the next several years."
Lilly funded this massive physical buildout through rapidly expanding operating cash flows—which rose from $4.24 billion in 2023 to $8.82 billion in 2024, and reached $16.81 billion in 2025—supplemented by targeted debt issuances to ensure capacity construction was never constrained by liquidity.
2. The Operational Bottleneck: Why Fill-Finish Dictates Market Share
In the commercialization of dual GIP/GLP-1 receptor agonists (such as tirzepatide, marketed as Mounjaro and Zepbound), the primary operational bottleneck was never consumer demand; it was the physical capability to assemble sterile, high-precision autoinjector pens at commercial scale:
- The CDMO Dependency Risk: Historically, large pharmaceutical companies relied on third-party CDMOs like Catalent, Lonza, and Vetter for sterile filling and finish. When Novo Nordisk’s parent company moved to privatize Catalent's key filling assets, it signaled that merchant CDMO capacity could be bought out from under competitors or prioritized away during periods of acute industry shortages.
- The Strategic Pivot: Rather than remaining exposed to vendor allocation decisions or regulatory scrutiny at third-party plants, Lilly verticalized the entire workflow. The company deployed tens of billions of dollars across major greenfield and brownfield sites—including massive expansions in Indiana (Lebanon), North Carolina (Research Triangle Park and Concord), Wisconsin (Pleasant Prairie), Ireland (Limerick), and Germany (Alzey).
- Engineering the Whole Device: Lilly’s internal plants are engineered to handle the complete chain: raw peptide synthesis, chemical purification, aseptic cold-chain vial and cartridge filling, and high-speed robotic assembly of the single-dose autoinjector pens.
3. Investment Implications of Lilly’s In-House Manufacturing Moat
From a fundamental investment perspective, Lilly’s aggressive capex deployment yields three critical economic advantages:
- Elimination of Counterparty and Supply-Poaching Risk: By owning the cleanrooms, isolators, and packaging lines, Lilly insulates its flagship cash-flow engine from external M&A maneuvers by peers. Control over batch release and regulatory compliance remains entirely in-house.
- Gross Margin Protection at Scale: While building internal facilities requires heavy upfront cash outflows, it converts variable vendor fee margins into fixed, depreciable assets. In fiscal 2025, Lilly achieved an audited gross margin of 83.0% and an operating margin of 45.6%, while generating an audited return on invested capital (ROIC) of 36.1%. As internal plants reach full commercial batch capacity, unit production costs drop significantly below external CDMO pricing.
- Capacity as a Barrier to Entry: A prospective competitor can discover an efficacious peptide or small-molecule GLP-1 candidate, but scaling commercial sterile filling to hundreds of millions of doses requires years of engineering lead time and billions in hard capital. Lilly’s front-loaded capital investments have widened its durable competitive moat, transforming what began as a defensive response to Novo’s Catalent buyout into an offensive scale advantage.
Research for information only, not investment advice. Figures reflect the dates shown; earlier sections are kept as written for the historical record.
Keep exploring
company · $LLY $ADM $PG
Eli Lilly Corporate Governance: Board Interlocks and Peptide CDMO Exposure
An examination of Eli Lilly's proxy filings shows that its board of directors maintains complete independence from primary merchant peptide CDMOs. While directors hold leadership roles at industrial and consumer companies such as ADM and Procter & Gamble, none possess overlapping ties to commercial peptide synthesis providers. Furthermore, Lilly's capital allocation strategy prioritizes vertical integration and direct ownership of manufacturing facilities over entangled third-party governance arrangements.
company · $LLY $OABI $ALNY
Eli Lilly & Co.: Insider Transactions, Governance Networks, and Strategic Affiliations
An analysis of Eli Lilly's Form 4 filings and proxy disclosures shows insider transactions dominated by routine tax withholdings and selective executive sales alongside significant top-line expansion. The company's board and executive ties link directly to biotechnology platforms such as OmniAb and Alnylam, consumer products leader Procter & Gamble, and technology partner NVIDIA. Concentrated institutional ownership, notably the 9.8% stake held by the Lilly Endowment, provides substantial structural protection as the company scales its cardiometabolic and oncology franchises.
company · $ONTO $KLAC $CAMT
Onto Innovation: Advanced Packaging Metrology and Valuation Analysis
Onto Innovation possesses a clean, net-cash balance sheet and strong strategic exposure to 2.5D/3D advanced packaging and optical critical dimension metrology. In fiscal 2024, the business delivered $987.3 million in revenue and $213.8 million in free cash flow, supported by structural demand for heterogeneous integration and panel-level packaging. However, with trailing multiples remaining elevated, normalized mid-cycle intrinsic value estimates between $115 and $130 per share suggest market pricing already reflects an optimistic super-cycle scenario.
company · $IBA
Industrias Bachoco: Operational Moats, Normalized Earnings, and Privatization Dynamics
Industrias Bachoco controls approximately 35% of Mexico's poultry production, underpinned by an extensive cold-chain and live-bird distribution logistics network and a debt-free balance sheet. Controlling shareholders initiated a take-private tender offer at approximately 81.66 MXN per share, representing an EV/EBITDA multiple of 4.0x to 4.5x funded largely by the company's own net cash holdings. Although normalized mid-cycle intrinsic value is appraised between 105 and 118 MXN per local share, delisting and ADR deregistration effectively eliminate public liquidity and minority protections.
company · $MSTR $RIOT
Strategy Inc: Debt Structure Covenants and Bitcoin Liquidation Mechanics
Strategy Inc's debt structure consists primarily of unsecured convertible senior notes that lack mark-to-market loan-to-value margin covenants or price-to-NAV thresholds, meaning equity discounts do not legally force Bitcoin liquidations. Despite negative operating cash flow (-$67.2 million in fiscal 2025) and preferred dividend burdens, the company maintains a dedicated $4.79 billion USD Reserve to service coupons and distributions. Direct asset liquidations would only occur if capital markets remain closed through the 2029–2032 convertible note maturity window after cash reserves are fully exhausted.
company · $MSTR $STRF $STRC
Index Exclusion and Capital Structure Stress: Strategy Inc. Case Study
Strategy Inc.'s removal from MSCI benchmark indexes forces passive funds to execute price-insensitive divestments, shifting market classification of the firm from an operating company to a closed-end asset vehicle. With its stock trading at a compressed 0.9x price-to-book multiple, the reflexive at-the-market equity issuance engine faces dilution constraints, sharply reducing weekly capital generation. Operating cash flow deficits from legacy enterprise software place the burden of servicing fixed debt interest and high-coupon preferred dividends onto existing cash reserves and potential asset sales.
company · $MSTR
Strategy Inc.: Capital Structure Stress and Forced Selling Mechanics
Strategy Inc. faces approximately $16.72 billion in cumulative senior claims, comprising $8.25 billion in debt and $8.47 billion in preferred stock notional value, against negative operating cash flows from its software business. While a $2.25 billion cash reserve provides a near-term buffer against immediate insolvency, an ongoing discount to net asset value impairs its primary at-the-market equity financing channel. In severe downturn scenarios where Bitcoin drops toward $25,000 or below, enterprise asset values fall below total senior obligations, eliminating residual common equity value.
company
Anthropic's Infrastructure Commitments: Free Cash Flow and Operational Leverage Analysis
Anthropic's aggregate committed spend under purchase commitments and lease agreements escalated to approximately $900.9 billion, with approximately $70.7 billion due over 12 months and $451.6 billion due before year-end 2030. These take-or-pay obligations convert variable compute expenses into massive, non-discretionary fixed cash requirements that mandate true-up payments regardless of actual utilization. Consequently, achieving positive free cash flow demands unprecedented revenue scale to outrun ongoing cash hurdles and continuous hardware reinvestment cycles.
industry · $DAL $UAL $AAL
Aviation Network Outages and Operating Leverage: Margin Risk Analysis
Large-scale aviation ground stops compress airline margins through lost passenger revenue and non-fuel cost surges from passenger duty-of-care reimbursements and stranded flight crews. Historical precedent demonstrates significant operating leverage; Delta Air Lines absorbed a $550 million pre-tax operating profit hit from approximately 7,000 cancellations over a five-day disruption. Disruption expenses also cause CASM ex-fuel to spike sharply, quickly turning marginal quarterly profits into losses for thin-margin or unprofitable carriers.